1194235-41-0

Basic information

• Product Name: Bortezomib Impurity 9
• Synonyms: Bortezomib Impurity 9;WXSBJLWLFBBGKF-LSQMVHIFSA-N;(R)-3-methyl-1-((S)-3-phenyl-2-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)propanamido)butylboronic acid
• CAS NO: 1194235-41-0
• Molecular Formula: C₂₈H₃₄BN₅O₅
• Molecular Weight: 531.41106
• Mol File: 1194235-41-0.mol

Chemical Properties

• Appearance: /
• Density: 1.227±0.06 g/cm3(Predicted)
• PKA: 9.69±0.43(Predicted)
• CAS DataBase Reference: Bortezomib Impurity 9(CAS DataBase Reference)
• NIST Chemistry Reference: Bortezomib Impurity 9(1194235-41-0)
• EPA Substance Registry System: Bortezomib Impurity 9(1194235-41-0)

Safety Data

• Hazardous Substances Data: 1194235-41-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Bortezomib Impurity 9 is used as a research compound for understanding the synthesis process, quality control, and potential applications of Bortezomib. It aids in the development of improved manufacturing techniques and the identification of novel therapeutic agents.
Used in Cancer Research:
Bortezomib Impurity 9 serves as a valuable tool in cancer research, enabling scientists to study the mechanisms of action and potential synergistic effects with other antitumor agents. This can lead to the discovery of new treatment strategies and the enhancement of existing therapies.
Used in Drug Development:
As a related compound to Bortezomib, Bortezomib Impurity 9 may have potential applications in drug development. It can be used to investigate the structure-activity relationship of proteasome inhibitors and contribute to the design of more effective and targeted cancer treatments.

Upstream product

• 98-97-5 2-pyrazylcarboxylic acid 
• 73058-37-4 N-(2-pyrazinylcarbonyl)-L-phenylalanine methyl ester 
• 1194235-14-7 N-(2-pyrazinecarbonyl)-L-phenylalanine-L-phenylalanine 
• 114457-94-2 (S)-3-phenyl-2[(pyrazine-2-carbonyl)-amino]propionic acid 
• 1194235-01-2 (S)-methyl 3-phenyl-2-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)-propanoate 
• 1194235-28-3 (+)-pinanediol N-(2-pyrazinecarbonyl)-L-phenylalanine-L-phenylalanine-L-leucineboronate 

Relevant articles and documents

TRIPEPTIDE BORONIC ACID OR BORONIC ESTER, PREPARATIVE METHOD AND USE THEREOF

The present invention discloses proteasome inhibitors of tripeptide boronic acids or boronic esters represented by Formula (I), preparative method and use thereof. The proteasome inhibitors are therapeutical agents for treating malignant tumor, various nervous system degenerative diseases, muscle cachexia or diabetes, wherein the malignant tumor is leukemia, gastric cancer, hepatocarcinoma or nasopharyngeal carcinoma.

Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors

A series of tripeptide boronate proteasome inhibitors were designed and synthesized on the basis of our previously built tripeptide aldehyde 3D-QSAR models. All the synthesized compounds were evaluated for their proteasome-inhibitory activities in an isolated 20S rabbit proteasome, and selected compounds were evaluated for their antitumor activities in vitro against four human cancer cell lines. Biological results showed bulky and negative substituents at P2 position improved the proteasome-inhibitory potency obviously, which completely conformed to the theoretical models, while those at P3 position thoroughly deviated from the 3D-QSAR model. Most of the screened compounds showed less than 1 nM inhibitory potency and high selectivity against 20S proteasome, of which 7f is the most potent (IC50 = 0.079 nM) and twofold more active than bortezomib (IC50 = 0.161 nM). Cell viability indicated hydrophilic 4-hydroxyphenyl substituent at P2 or P3 position was not favorable to the cellular activities. Especially for the two hematologic cancer cell lines, HL-60 and U266, 7f inhibited them at the level of less than 10 nM and was more potent than the control bortezomib. It is being considered a promising new lead to be developed for the treatment of various cancers.